...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Ultrasound in Medicine and Biology >New integrated imaging high intensity focused ultrasound probe for transrectal prostate cancer treatment.
【24h】

New integrated imaging high intensity focused ultrasound probe for transrectal prostate cancer treatment.

机译：用于经直肠前列腺癌治疗的新型集成成像高强度聚焦超声探头。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The present study proposes a new integrated imaging (II) high-intensity focused ultrasound (HIFU) probe intended as an improvement to the Ablatherm prostate cancer treatment. Because of a perforation in the center of the II probe, the expected lesion differs from the one obtained for the original Ablatherm probe. In this paper, the new geometry and the strategy followed to establish the treatment parameters are presented. The original probe has a 40-mm focal length, a 50-mm aperture and is truncated at 31 mm. The II probe has a 45-mm focal length, a 61-mm aperture, a central perforation of 25 mm and is truncated at 31 mm. Both probes operate at 3 MHz. A mathematical model for lesion prediction was used for setting the treatment parameters for the II probe. These parameters should ensure equivalence between the lesions obtained with the original and II probes. Simulation-obtained parameters were validated by in-vitro and in-vivo (on liver of 70 New Zealand rabbits) experiments. The new II probe was usedclinically to treat 30 patients. The mean age was 70.9 +/- 5.3 years (SD), the mean prostate volume 26.9 +/- 7.7 mL and the mean serum prostate specific antigen (PSA) concentration before treatment was 9.2 +/- 5.5 ng/mL. Simulations showed that for the II probe acoustical power and duration when the transducer is inactive should be reduced of 14% and 1s. In-vitro and in-vivo experiments confirmed the equivalence between the lesions obtained with the two probes. The lesion volume obtained under in-vitro conditions (for a traversed tissue depth of 16 mm to the focus) was 5 +/- 0.4 cm(3) and 5.1 +/- 0.5 cm(3) for the original and II probes, respectively. Under in-vivo conditions, the lesion volume (for a traversed tissue depth of 18 mm) was 5.3 +/- 1.1 cm(3) and 5.1 +/- 1.1 cm(3) for the original and II probes, respectively. During the clinical trial, a correction of + 1s in the exposure time was required to recreate the same degree of efficacy observed with the original probe (p = 0.97): 66.7 % of negative biopsies and 75% of patients with PSA at 3 mo < or =1 ng/mL. The morbidity observed was minimal and identical to that observed with the original probe.
机译：本研究提出了一种新的集成成像（II）高强度聚焦超声（HIFU）探针，旨在改善Ablatherm前列腺癌的治疗方法。由于II探针中心的穿孔，预期的病变与原始Ablatherm探针获得的病变不同。本文介绍了新的几何形状和建立处理参数所遵循的策略。原始探针的焦距为40毫米，孔径为50毫米，并被截断为31毫米。 II型探针的焦距为45毫米，孔径为61毫米，中心孔为25毫米，截短为31毫米。两个探头的工作频率均为3 MHz。用于病变预测的数学模型用于设置II探针的治疗参数。这些参数应确保使用原始探针和II探针获得的病灶相等。仿真获得的参数通过体外和体内实验（在70只新西兰兔的肝脏上）进行验证。新的II型探针在临床上用于治疗30例患者。治疗前的平均年龄为70.9 +/- 5.3岁（SD），平均前列腺体积为26.9 +/- 7.7 mL，平均血清前列腺特异性抗原（PSA）浓度为9.2 +/- 5.5 ng / mL。仿真表明，对于II探头，当换能器不工作时，声功率和持续时间应分别降低14％和1s。体外和体内实验证实了用两种探针获得的病变之间的等效性。对于原始探头和II型探头，在体外条件下（对于到达焦点的16 mm横穿组织深度），病变体积分别为5 +/- 0.4 cm（3）和5.1 +/- 0.5 cm（3）。 。在体内条件下，原始探头和II型探头的病变体积（对于18 mm的横穿组织深度）分别为5.3 +/- 1.1 cm（3）和5.1 +/- 1.1 cm（3）。在临床试验期间，需要校正暴露时间+ 1 s，以恢复与原始探针所观察到的相同程度的功效（p = 0.97）：66.7％的活检阴性和75％的PSA患者在3 mo <或= 1 ng / mL。观察到的发病率极低，与原始探针观察到的发病率相同。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号